Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C and HIV Coinfection => Topic started by: Hep Editors on April 27, 2017, 10:01:42 am
-
AbbVie’s investigational hepatitis C virus (HCV) treatment glecaprevir/pibrentasvir, known as G/P, boasts high cure rates among those coinfected with HIV and multiple genotypes of HCV, including those with and without compensated cirrhosis.
The drug company applied for FDA approval of G/P in February. A decision is expected in late June.
For more...
https://www.hepmag.com/article/excellent-results-abbvies-hep-c-treatment-gp-hiv